MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

6.360 +1.710 (+36.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Polaryx Therapeutics, Inc. - Common Stock

News headline image
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day. 
Via Stocktwits
Topics ETFs
News headline image
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's Going On With Polaryx Therapeutics Stock Wednesday? ↗
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement. 
Via Benzinga
News headline image
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans ↗
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders. 
Via Benzinga
News headline image
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil) 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Welcomes New Members of the Board of Directors
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug... 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story